Date: 2016-11-04
Type of information: Development agreement
Compound: HPV (human papilloma virus) vaccine
Company: Artes Biotechnology (Germany) BioSun Pharmed (Iran)
Therapeutic area: Cancer - Oncology - Infectious diseases
Type agreement: development manufacturing production
Action mechanism: vaccine.
Disease: human papilloma virus infection
Details: * On November 4, 2016, Artes Biotechnology and BioSun Pharmed announced to join forces for the development and manufacturing of a HPV (human papilloma virus) vaccine in Iran. The agreed long-term collaboration involved the strength of both partners. Artes Biotechnology is specialized in cell line and process development of virus like particle (VLP) based vaccines and in technology transfer for pharmaceutically relevant production processes. BioSun Pharmed Co is involved in the manufacturing of high quality and safe vaccines and biopharmaceutical products for the domestic and international markets. Artes will be responsible for process development of API, formulation, quality control and supply of preclinical test material. In addition, Artes will be engaged in design of the manufacturing site at BioSun and in selection of third parties for GMP manufacturing.
Biosun Pharmed is a leading Iranian biopharmaceutical developer/manufacturer and a pioneer in mass-production of GMP biopharmaceuticals in the region targeting local and international markets. The company started its activity from 2012, aiming to produce strategic and vital biotechnological products from API to finished dosage forms, using the latest knowledge and technologies based on local and global standards. Company’s activities are categorized in four main areas (biosimilars, peptides, vaccines and mAbs). Based on this, Biosun is making agreements for co-development of targeted products with knowledgeable and high-tech companies.
Financial terms: Financial details of this agreement were not disclosed.
Latest news:
